Isolated hyperthermic limb perfusion with melphalan and tumour necrosis factor in malignant melanoma;Die isolierte hypertherme Extremitatenperfusion beim malignen Melanom mit Melphalan und Tumornekrosefaktor

Deutsche Medizinische Wochenschrift

Volumn 122, Issue 7, 1997, Pages 177-181

  Kettelhack, C ^a   Hohenberger, P ^a   Schlag, P M ^a  

^a Section of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HYPERTHERMIA; LIMB PERFUSION; MALE; MELANOMA; LIMB; MIDDLE AGED; MONITORING; REGIONAL PERFUSION; REMISSION; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; HUMANS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030615144     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1047593     Document Type: Article

References (17)

1. Cavaliere, R., E. C. Ciocatto, B. C. Giovanella, C. Heidelberger, R. O. Johnson, M. Margottini, B. Mondovi, G. Moricca, A. Rossi-Fanelli: Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 20 (1967), 1351-1381.
2. Creech, O., E. T. Krementz, R. F. Ryan, J. N. Winblad: Chemotherapy of cancer. Regional perfusion utilizing an extracorporeal circuit. Ann. Surg. 148 (1958), 616-631.
3. Fraker, D. L., H. R. Alexander: The use of tumour necrosis factor (TNF) in isolated perfusion. Results and side effects. The NCl results. Melanoma Res 4, Suppl. 1 (1994), 27-29.
4. Gerain, J., D. Lienard, P. Ewalenko, F. J. Lejeune: High serum levels of TNF-α after its administration for isolation perfusion of the limb. Cytokine 4 (1992), 585-591.
5. Hafström, L., J. Mattson: Regional chemotherapy for malignant melanoma. Cancer Treatm. Rev. 19 (1993), 17-28.
6. Haier, J., P. Hohenberger, P. M. Schlag: Kontinuierliches Monitoring kardiozirkulatorischer Effekte der isolierten hyperthermen Extremiaätenperfusion mit rhTNFalpha/Melphalan mit der Thermodilutionsmethode. Langenbecks Arch. Chir. Suppl. Kongressbd (1995), 251-257.
7. Kettelhack, C., T. Kraus, T. Hupp, M. Manner, P. Schlag: Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Europ. J. surg. Oncol. 16 (1990), 370-375.
8. Lejeune, F. I., D. Lienard, M. El Douaihy, J. Vadoud Seyedi, P. Ewalenko: Results of 206 isolated limb perfusions for malignant melanoma. Europ. J. surg. Oncol. 15 (1989), 510-519.
9. Lienard, D., A. M. M. Eggermont, H. Schraffordt Koops, B. B. R. Kroon, F. Rosenkaimer, P. Autier, F. J. Lejeune: Isolated perfusion of the limb with high-dose tumor necrosis factor alpha (TNFα), interferon-gamma (IFN-γ) and melphalan for melanoma stage III. Results of a multicentre pilot study. Melanoma Res. 4 (S1) (1994), 21-26.
10. Lienard, D., P. Ewalenko, J. J. Delmotte, F. J. Lejeune: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. clin. Oncol. 10 (1992), 52-60.
11. Sprenger, H.-J., J. Markwardt, P. M. Schlag: Quantitative Leckbestimmung bei der isolierten Extremitätenperfusion. Nucl. Med. 33 (1994), 248-253.
12. Stehlin, J. S., B. C. Giovanella, P. D. deIpolyi, L. R. Muenz, R. F. Anderson: Results of hyperthermic perfusion for melanoma of the extremities. Surg. Gynecol. Obstet. 140 (1975), 339-348.
13. Thorn, A. K., H. R. Alexander, M. P. Andrich, W. C. Barker, S. A. Rosenberg, D. L. Fraker: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon-gamma, and melphalan. J. Clin. Oncol. 13 (1995), 264-273.
14. Thompson, J. F., M. P. Gianoutsos: Isolated limb perfusion for melanoma. Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. Wld. J. Surg. 16 (1992), 227-233.
15. Vaglini, M., F. Belli, M. Ammatuna, M. G. Inglese, R. Manzi, A. Prada, L. Persiani, M. Santinami, N. Santoro, N. Cascinelli: Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 73 (1994), 483-492.
16. Vaglini, M., F. Belli, M. Santinami: Isolation perfusion of the lower limb with platinum. Wld. J. Surg. 12 (1988), 307-309.
17. Wieberdink, J., C Benckhuysen, R. P. Braat, E. A. Van Slooten, G. A. A. Olthuis: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Europ. J. Cancer clin. Oncol. 18 (1982), 905-910.